(Q40146009)

English

Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.

scientific article published on May 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

0 references

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Takuo Ito

1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Hideo Tanaka

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Akiro Kimura

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

European Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

78

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

417-431

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

describes a project that uses

0 references

0 references

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Chronic myeloid leukemia-still a few questions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Requirement of Src kinase Lyn for induction of DNA synthesis by granulocyte colony-stimulating factor.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2007.00835.X

21 January 2018

Identifiers

10.1111/J.1600-0609.2007.00835.X

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40146009&oldid=1635519994"